Multiple system atrophy – the cousin of Parkinson's disease. MSA is a degenerative brain disorder that impairs the body's functions, including blood pressure, heart rate, bladder function and is related to Parkinson's disease.
Progressive supranuclear palsy is rare. It may be easily mistaken for Parkinson disease, which is much more common and has similar symptoms. But with PSP, speech and difficulty swallowing are usually affected more significantly than with Parkinson disease.
There's currently no cure for MSA and no way of slowing its progression. People with the condition typically live for 6 to 9 years after their symptoms start and may get worse quickly during this time. Some people may live for more than 10 years after being diagnosed.
Definition. Multiple system atrophy- parkinsonian type (MSA-P) is a rare condition that causes symptoms similar to Parkinson disease. However, people with MSA-P have more widespread damage to the part of the nervous system that controls important functions such as heart rate, blood pressure, and sweating.
MSA affects men and women equally, with an average age of onset of approximately 55 years [2, 3]. The mean life expectancy following diagnosis is 7 years [6].
Though dementia is not considered a common characteristic of MSA, cognitive impairment occurs in some patients in the form of loss of verbal memory and verbal fluency1.
There's no cure for multiple system atrophy. Managing the disease involves treating signs and symptoms to make you as comfortable as possible and to maintain your body functions. To treat specific signs and symptoms, your doctor may recommend: Medications to raise blood pressure.
Inheritance. Most cases of multiple system atrophy are sporadic, which means they occur in people with no history of the disorder in their family. Rarely, the condition has been reported to run in families; however, it usually does not have a clear pattern of inheritance.
While genetics is thought to play a role in Parkinson's, in most cases the disease does not seem to run in families. Many researchers now believe that Parkinson's results from a combination of genetic and environmental factors, such as exposure to toxins.
PSP is often misdiagnosed as Parkinson's disease, especially early in the disorder, as they share many symptoms, including stiffness, movement difficulties, clumsiness, bradykinesia (slow movement), and rigidity of muscles. However, PSP progresses more rapidly than Parkinson's disease.
Genetics. A number of genetic factors have been shown to increase a person's risk of developing Parkinson's disease, although exactly how these make some people more susceptible to the condition is unclear. Parkinson's disease can run in families as a result of faulty genes being passed to a child by their parents.
Available studies have shown that compared with healthy controls, patients with PD are accompanied by high rates of premature death. This is usually caused by factors such as pneumonia and cerebrovascular and cardiovascular diseases.
It's possible for non-motor symptoms to start occurring up to a decade before any motor symptoms emerge. Years can pass before symptoms are obvious enough to make a person to go to the doctor.
"Probably the biggest driving factor, and still remains the biggest risk factor for Parkinson disease, is age. We have an aging population.
Appetite reduces and weight loss is apparent. Communication becomes too effortful and breathing more bubbly or shallow. Dying is very rarely a dramatic event. In the majority of cases it is an increasing winding down of all bodily functions and everything stopping, death occurring in a peaceful and dignified manner.
Sleep and breathing problems are very common in MSA patients. Sleep apnea (momentary lapses in breathing), respiratory stridor (noisy breathing), REM behavior disorder (shouting and acting out dreams) and excessive daytime sleepiness can be among the earliest symptoms of MSA.
MSA Life Expectancy (Prognosis)
Prognosis is currently guarded, with most MSA patients passing away from the disease or its complications within 6-10 years after the onset of symptoms.
Because MSA is at this time a terminal disease with mean patient survival of 6 to 10 years after the onset of symptoms, patients and families should begin to make decisions regarding advanced directives, finances, hospice care, and the possibility of brain donation, if so desired.
In MSA there may be several stages -- alpha-synuclein accumulates in the oligodendroglial cells, then there is failure of mitochondrial function as well as loss of trophic factor support. Then the oligodendroglia degenerate, followed by microglia and astroglial activation.
The feelings of fatigue that are common with MSA can contribute to feeling low in mood. Conversely, low mood, depression and anxiety can contribute to feelings of lethargy. Carers may also feel very tired or low at times, due to the ongoing physical, practical and emotional support they are providing.
PD and MSA patients are prone to pain with insufficient treatment.
The progression of MSA varies, but the condition does not go into remission. As the disorder progresses, daily activities become more difficult. Possible complications include: Breathing problems during sleep.
This past March, the FDA granted the drug fast track designation for the treatment of MSA. “Biohaven sees the potential for verdiperstat to be the first disease-modifying treatment for MSA. No disease-modifying treatments currently exist for MSA; only symptomatic and palliative therapies are available,” Qureshi said.